Description
Glycemic control: JARDIANZ® DUO is indicated as a complementary treatment to the diet and exercise regimen to improve glycemic control in adult patients with type 2 diabetes mellitus.
• When treatment with empagliflozin and metformin is appropriate.
• In whom adequate control is not achieved with metformin or empagliflozin monotherapy.
• In which adequate control is not achieved with empagliflozin or metformin in combination with other hypoglycaemic agents, including insulin (see section “Clinical studies”).
• Who are already receiving treatment with empagliflozin and metformin co-administered as tablets with each drug separately.
Prevention of cardiovascular events: JARDIANZ® DUO is indicated in patients with type 2 diabetes mellitus and high cardiovascular risk when treatment with empagliflozin and metformin is appropriate and empagliflozin is necessary to reduce the risk of:
• All-cause mortality by reducing cardiovascular death.
• Cardiovascular death or hospitalization for heart failure.






Reviews
There are no reviews yet.